Insmed Incorporated
INSMDrugs in Pipeline
18
Phase 3 Programs
10
Upcoming Catalysts
1
Next Catalyst
Next quarter
Market Overview
Stock performance and key metrics
1 upcoming, 1 past
How INSM's past catalysts played out
LAI 590 mg
NTM Lung Infection Due to MAC
Liposomal amikacin for inhalation
Cystic Fibrosis
Treprostinil Palmitil
Pulmonary Hypertension
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.
Pseudomonas Aeruginosa Infection
ALIS
Mycobacterium Infections, Nontuberculous
LAI (Liposomal Amikacin for Inhalation) 590 mg
Mycobacterium Infections, Nontuberculous
Brensocatib 10 mg
Non-Cystic Fibrosis Bronchiectasis
rhIGF-I/rhIGFBP-3
Myotonic Dystrophy Type 1
Treprostinil Palmitil Inhalation Powder
Pulmonary Hypertension
Brensocatib 25 mg
Non-Cystic Fibrosis Bronchiectasis
ARIKACE™
Cystic Fibrosis
Cisplatin liposomal
Osteosarcoma Metastatic
Arikayce™ 560 mg
Cystic Fibrosis
Mometasone furoate nasal spray (MFNS)
Chronic Rhinosinusitis Without Nasal Polyps
280 mg Arikayce™
Bronchiectasis
Liposomal amikacin for inhalation (LAI)
Mycobacterium Infections, Nontuberculous
Brensocatib
Hidradenitis Suppurativa
Arikayce™
Cystic Fibrosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
LAI 590 mg | Phase 3 | NTM Lung Infection Due to MAC | - | - |
Liposomal amikacin for inhalation | Phase 3 | Cystic Fibrosis | - | - |
Treprostinil Palmitil | Phase 3 | Pulmonary Hypertension | - | - |
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. | Phase 3 | Pseudomonas Aeruginosa Infection | - | - |
ALIS | Phase 3 | Mycobacterium Infections, Nontuberculous | - | - |
LAI (Liposomal Amikacin for Inhalation) 590 mg | Phase 3 | Mycobacterium Infections, Nontuberculous | - | - |
Brensocatib 10 mg | Phase 3 | Non-Cystic Fibrosis Bronchiectasis | - | - |
rhIGF-I/rhIGFBP-3 | Phase 3 | Myotonic Dystrophy Type 1 | - | - |
Treprostinil Palmitil Inhalation Powder | Phase 3 | Pulmonary Hypertension | - | - |
Brensocatib 25 mg | Phase 3 | Non-Cystic Fibrosis Bronchiectasis | - | - |
ARIKACE™ | Phase 2 | Cystic Fibrosis | - | - |
Cisplatin liposomal | Phase 2 | Osteosarcoma Metastatic | - | - |
Arikayce™ 560 mg | Phase 2 | Cystic Fibrosis | - | - |
Mometasone furoate nasal spray (MFNS) | Phase 2 | Chronic Rhinosinusitis Without Nasal Polyps | - | - |
280 mg Arikayce™ | Phase 2 | Bronchiectasis | - | - |
Liposomal amikacin for inhalation (LAI) | Phase 2 | Mycobacterium Infections, Nontuberculous | - | - |
Brensocatib | Phase 2 | Hidradenitis Suppurativa | - | - |
Arikayce™ | Phase 2 | Cystic Fibrosis | - | - |
Cystic Fibrosis
5 drugs in this indication
Mycobacterium Infections, Nontuberculous
3 drugs in this indication
Non-Cystic Fibrosis Bronchiectasis
2 drugs in this indication
Pulmonary Hypertension
2 drugs in this indication
Hidradenitis Suppurativa
1 drug in this indication
NTM Lung Infection Due to MAC
1 drug in this indication
Myotonic Dystrophy Type 1
1 drug in this indication
Osteosarcoma Metastatic
1 drug in this indication
Pseudomonas Aeruginosa Infection
1 drug in this indication
Bronchiectasis
1 drug in this indication
Chronic Rhinosinusitis Without Nasal Polyps
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Insmed Incorporated's drug pipeline?→
CatalystAlert tracks 18 drug candidates in Insmed Incorporated's (INSM) pipeline across Phase 3, Phase 2. Its lead program is LAI 590 mg (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Insmed Incorporated's next FDA catalyst?→
Insmed Incorporated's (INSM) next tracked catalyst is a Phase 3 expected December 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track INSM biotech catalysts?→
Add INSM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Insmed Incorporated's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.